ADMA Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of 29.96% compared to ADMA Biologics's net margin of 25.86%. ADMA Biologics's return on equity of 39.59% beat Corcept Therapeutics's return on equity of 25.77%.

ADMA Biologics has a consensus price target of $24.62, signalling upside risk potential of 41.4%. On the other hand Corcept Therapeutics has an analysts' consensus of -- which suggests that it could grow by 43.57%. Given that Corcept Therapeutics has higher upside potential than ADMA Biologics, analysts believe Corcept Therapeutics is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.702, which suggesting that the stock is 29.754% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.513, suggesting its less volatile than the S&P 500 by 48.73%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $119.8M, which are smaller than Corcept Therapeutics quarterly revenues of $182.5M. ADMA Biologics's net income of $35.9M is lower than Corcept Therapeutics's net income of $47.2M. Notably, ADMA Biologics's price-to-earnings ratio is 62.18x while Corcept Therapeutics's PE ratio is 41.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.79x versus 9.25x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of 29.96% compared to ADMA Biologics's net margin of 34.1%. ADMA Biologics's return on equity of 39.59% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

ADMA Biologics has a consensus price target of $24.62, signalling upside risk potential of 41.4%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 49.17%. Given that Catalyst Pharmaceuticals has higher upside potential than ADMA Biologics, analysts believe Catalyst Pharmaceuticals is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.702, which suggesting that the stock is 29.754% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.748, suggesting its less volatile than the S&P 500 by 25.213%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $119.8M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $128.7M. ADMA Biologics's net income of $35.9M is lower than Catalyst Pharmaceuticals's net income of $43.9M. Notably, ADMA Biologics's price-to-earnings ratio is 62.18x while Catalyst Pharmaceuticals's PE ratio is 18.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.79x versus 5.72x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech has a net margin of 29.96% compared to ADMA Biologics's net margin of 32.42%. ADMA Biologics's return on equity of 39.59% beat Krystal Biotech's return on equity of 6.45%.

ADMA Biologics has a consensus price target of $24.62, signalling upside risk potential of 41.4%. On the other hand Krystal Biotech has an analysts' consensus of $207.78 which suggests that it could grow by 31.07%. Given that ADMA Biologics has higher upside potential than Krystal Biotech, analysts believe ADMA Biologics is more attractive than Krystal Biotech.

ADMA Biologics has a beta of 0.702, which suggesting that the stock is 29.754% less volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.799, suggesting its less volatile than the S&P 500 by 20.116%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $119.8M, which are larger than Krystal Biotech quarterly revenues of $83.8M. ADMA Biologics's net income of $35.9M is higher than Krystal Biotech's net income of $27.2M. Notably, ADMA Biologics's price-to-earnings ratio is 62.18x while Krystal Biotech's PE ratio is 89.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.79x versus 19.31x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 29.96% compared to ADMA Biologics's net margin of 7.2%. ADMA Biologics's return on equity of 39.59% beat Sarepta Therapeutics's return on equity of 12.48%.

ADMA Biologics has a consensus price target of $24.62, signalling upside risk potential of 41.4%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 51.85%. Given that Sarepta Therapeutics has higher upside potential than ADMA Biologics, analysts believe Sarepta Therapeutics is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.702, which suggesting that the stock is 29.754% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $119.8M, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. ADMA Biologics's net income of $35.9M is higher than Sarepta Therapeutics's net income of $33.6M. Notably, ADMA Biologics's price-to-earnings ratio is 62.18x while Sarepta Therapeutics's PE ratio is 79.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.79x versus 7.48x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.